NEPHROLOGY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Key Developments

• On January 17, 2024, Sun Pharma, a pharmaceutical company, announced a partnership with Bayer AG, a Germany-based multinational pharmaceutical and biotechnology company, to market a drug designed for treating chronic kidney disease and other conditions. As per the agreement, Bayer AG has provided Sun Pharma with non-exclusive rights to distribute and market a second Finerenone product named Lyvelsa.
• Everest Medicines, a biopharmaceutical firm specializing in discovering, clinically developing, manufacturing, and commercializing innovative medicines and vaccines, announced the successful launch of NEFECO in China. This launch signifies a significant advancement in patient care for IgA nephropathy (IgAN) in the region.
• The Central Drugs Standard Control Organisation (CDSCO) had granted approval for Jardiance (empagliflozin) 10 mg tablets. This approval allows for the reduction of the risk of sustained decline in individuals with end-stage kidney disease, cardiovascular death, and hospitalization in adults diagnosed with chronic kidney disease (CKD) who are at risk of disease progression.
• Novartis, a innovative medicines company, presented results from the Phase III APPLAUSE-IgAN study of Fabhalta (iptacopan) at the World Congress of Nephrology in Buenos Aires, Argentina. Fabhalta, an investigational Factor B inhibitor for IgA nephropathy (IgAN), showed promising outcomes. Patients treated with Fabhalta achieved a significant 38.3% reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 9 months compared to those receiving placebo alongside standard supportive care (p<0.0001).